Seyfi Arslan | Dicle University (original) (raw)

Papers by Seyfi Arslan

Advances in Therapy, 2007

Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer's ... more Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer's disease (AD). The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Fifteen patients who fulfilled the clinical criteria for probable AD of mild to moderate severity, as put forth by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association, and as specified by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were included in the study. A control group of 15 healthy individuals from the same age and education range was included in the study.

Neurosciences, Apr 1, 2008

T he so-called "stroke," meaning the sudden occlusion of one or more brain vessels resulting in a... more T he so-called "stroke," meaning the sudden occlusion of one or more brain vessels resulting in an insufficient perfusion of the associated brain area, presents, together with cardiovascular diseases, and cancer. 1 Treatment of stroke is still limited to the optimal supportive measures. Any therapeutic approach in stroke promising to ABSTRACT ‫في‬ ‫اإلحتشاء‬ ‫حجم‬ ‫على‬ ‫ميمانتني‬ ‫عقار‬ ‫آثار‬ ‫تقييم‬ ‫األهداف:‬ ‫مؤقت‬ ‫إغالق‬ ‫عملية‬ ‫إجراء‬ ‫بعد‬ ‫العصبية‬ ‫والنتائج‬ ‫املخ‬ ‫تروية‬ ‫نقص‬ ‫الدماغي‬ )MCAO( ‫اجلرذان‬ ‫لدى‬ ‫التغطية‬ ‫وإعادة‬ ‫للشريان‬ ‫الوسطي.‬ ‫في‬ ‫داولي‬ ‫سبراكيو-‬ ‫نوع‬ ‫من‬ ً ‫بالغا‬ ً ‫جرذا‬ 30 ‫استخدام‬ ‫الطريقة:‬ ‫طريقة‬ ‫بواسطة‬ ‫الدماغ‬ ‫في‬ ‫التروية‬ ‫نقص‬ ‫إجراء‬ ‫مت‬ ‫الدراسة.‬ ‫هذه‬ ‫إعادة‬ ‫متت‬ .4-0 ‫النايلون‬ ‫غرز‬ ‫باستخدام‬ ‫اللمعة‬ ‫داخل‬ ‫اللهيب‬ ‫الدماغي‬ ‫للشريان‬ ‫اإلغالق‬ ‫عملية‬ ‫إجراء‬ ‫من‬ ‫ساعتني‬ ‫بعد‬ ‫التغطية‬ ‫مجموعتني‬ ‫الى‬ ‫عشوائي‬ ‫بشكل‬ ‫اجلرذان‬ ‫تقسيم‬ ‫مت‬ ‫الوسطي.‬ ‫ميمانتني).‬ ‫عقار‬ ‫تلقت‬ ‫التي‬ ‫و(املجموعة‬ ‫التحكم)‬ ‫(مجموعة‬ ‫وعقار‬ )0.5ml/kg( 0.9% ‫امللحي‬ ‫احمللول‬ ‫املجموعة‬ ‫تلقت‬ ‫احلصول‬ ‫مت‬ ‫املعدي.‬ ‫األنبوب‬ ‫طريق‬ ‫عن‬ )30mg/kg( ‫ميمانتني‬ ‫وجذع‬ ‫واملخيخ‬ ‫املخ‬ ‫من‬ ‫مليمترين‬ ‫بسماكة‬ ‫تاجية‬ ‫شرائح‬ ‫ثالث‬ ‫على‬ ‫تريفينيلتيترازوليوم.‬ ‫كلوريد‬ ‫من‬ 2% ‫مبحلول‬ ‫صبغها‬ ‫ومت‬ ‫الدماغ‬ ‫الدماغ‬ ‫مناطق‬ ‫قياس‬ ‫ومت‬ ‫جزء‬ ‫كل‬ ‫على‬ ‫الشفافة‬ ‫الصفحات‬ ‫وضع‬ ‫مت‬ ‫واالحتشاءات.‬ ‫(املجموع‬ ‫مجموعة‬ ‫كل‬ ‫من‬ ‫شريحة‬ 45 ‫على‬ ‫احلصول‬ ‫مت‬ ‫النتائج:‬ ‫وجذع‬ ‫واملخيخ‬ ‫املخ‬ ‫في‬ ‫بالدم‬ ‫التروية‬ ‫نقص‬ ‫منطقة‬ ‫نسبة‬ .)90 ‫التحكم‬ ‫مجموعة‬ ‫من‬ ‫أعلى‬ ‫ميمانتني‬ ‫مجموعة‬ ‫في‬ ‫الدماغ‬ ‫التحسن‬ ‫نقاط‬ ‫حددنا‬ ‫فقد‬ ‫ذلك‬ ‫إلى‬ ‫باإلضافة‬ )p>0.0001( ‫عقار‬ ‫تلقت‬ ‫التي‬ ‫اجلرذان‬ ‫في‬ ‫ساعة‬ ‫و27‬ 24 ‫عند‬ ‫العصبية‬ ‫وذو‬ ‫أفضل‬ ‫شفاء‬ ‫ميمانتني‬ ‫عقار‬ ‫مجموعة‬ ‫على‬ ‫ظهر‬ ‫ميمانتني.‬ ‫التحكم.‬ ‫مجموعة‬ ‫من‬ ‫إحصائية‬ ‫داللة‬ )p>0.0001( ‫الدم‬ ‫تروية‬ ‫نقص‬ ‫منطقة‬ ‫من‬ ‫يخفض‬ ‫قد‬ ‫ميمانتني‬ ‫عقار‬ ‫إن‬ ‫خامتة:‬ ‫يتم‬ ‫قد‬ ‫أنه‬ ‫ويبدو‬ ‫التجربة‬ ‫عليها‬ ‫أجريت‬ ‫التي‬ ‫اجلرذان‬ ‫لدى‬ ‫للدماغ‬ ‫الدماغ.‬ ‫تروية‬ ‫نقص‬ ‫في‬ ‫ميمانتني‬ ‫عقار‬ ‫من‬ ‫االستفادة‬ Objective: To evaluate the effects of memantine on infarct size in cerebral ischemia and on neurological outcome after temporary middle cerebral artery occlusion )MCAO( and reperfusion in rats.

Neurosciences (Riyadh, Saudi Arabia), 2008

To evaluate the effects of memantine on infarct size in cerebral ischemia and on neurological out... more To evaluate the effects of memantine on infarct size in cerebral ischemia and on neurological outcome after temporary middle cerebral artery occlusion (MCAO) and reperfusion in rats. In this study, performed between 2002-2004 in Dicle University School of Medicine, Diyarbakir, Turkey, 30 adult Sprague-Dawley rats were used. Cerebral ischemia was constituted by the intraluminal filament method with a 4-0 nylon suture. Reperfusion was started after 2 hours of MCAO. The rats were randomly divided into 2 groups as control and memantine. Saline 0.9% (0.5 ml/kg) and memantine (30 mg/kg) were administered via nasogastric intubations. Three coronal slices of 2 mm thickness were obtained from cerebrum, cerebellum, and brain stem, and were stained with a 2% solution of triphenyltetrazolium chloride. Transparent sheets were placed over each section and the areas of the brain and infarct were measured. Forty-five slices from each group (total 90) were obtained. Percent of ischemic area (%) in c...

Advances in Therapy, 2007

Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer&am... more Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer's disease (AD). The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Fifteen patients who fulfilled the clinical criteria for probable AD of mild to moderate severity, as put forth by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association, and as specified by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were included in the study. A control group of 15 healthy individuals from the same age and education range was included in the study. Before treatment was begun, Mini Mental State Examination (MMSE) tests were performed on all patients to evaluate cognitive function. All patients underwent baseline SPECT for evaluation of 25 different brain regions. Rivastigmine 3 mg/d was given for the first 4 wk of treatment; the dosage was then increased to 6 mg/d. The MMSE and SPECT were repeated 6 mo after the start of treatment. SPECT findings revealed that rivastigmine did not significantly affect brain perfusion in AD cases except in the inferior frontal lobe, despite stabilization and improvement noted in MMSE scores during treatment. Rivastigmine treatment of patients with AD did not significantly change brain perfusion as seen on SPECT, except in the inferior frontal lobe, but cognitive performance was stabilized or improved during the treatment course. These findings suggest the need for additional, larger studies to investigate the effects of acetylcholinesterase inhibitors on regional cerebral blood flow.

Advances in Therapy, 2007

Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer’s ... more Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer’s disease (AD). The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Fifteen patients who fulfilled the clinical criteria for probable AD of mild to moderate severity, as put forth by the National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association, and as specified by theDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were included in the study. A control group of 15 healthy individuals from the same age and education range was included in the study. Before treatment was begun, Mini Mental State Examination (MMSE) tests were performed on all patients to evaluate cognitive function. All patients underwent baseline SPECT for evaluation of 25 different brain regions. Rivastigmine 3 mg/d was given for the first 4 wk of treatment; the dosage was then increased to 6 mg/d. The MMSE and SPECT were repeated 6 mo after the start of treatment. SPECT findings revealed that rivastigmine did not significantly affect brain perfusion in AD cases except in the inferior frontal lobe, despite stabilization and improvement noted in MMSE scores during treatment. Rivastigmine treatment of patients with AD did not significantly change brain perfusion as seen on SPECT, except in the inferior frontal lobe, but cognitive performance was stabilized or improved during the treatment course. These findings suggest the need for additional, larger studies to investigate the effects of acetylcholinesterase inhibitors on regional cerebral blood flow.

Advances in Therapy, 2007

Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer’s ... more Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer’s disease (AD). The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Fifteen patients who fulfilled the clinical criteria for probable AD of mild to moderate severity, as put forth by the National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association, and as specified by theDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were included in the study. A control group of 15 healthy individuals from the same age and education range was included in the study. Before treatment was begun, Mini Mental State Examination (MMSE) tests were performed on all patients to evaluate cognitive function. All patients underwent baseline SPECT for evaluation of 25 different brain regions. Rivastigmine 3 mg/d was given for the first 4 wk of treatment; the dosage was then increased to 6 mg/d. The MMSE and SPECT were repeated 6 mo after the start of treatment. SPECT findings revealed that rivastigmine did not significantly affect brain perfusion in AD cases except in the inferior frontal lobe, despite stabilization and improvement noted in MMSE scores during treatment. Rivastigmine treatment of patients with AD did not significantly change brain perfusion as seen on SPECT, except in the inferior frontal lobe, but cognitive performance was stabilized or improved during the treatment course. These findings suggest the need for additional, larger studies to investigate the effects of acetylcholinesterase inhibitors on regional cerebral blood flow.

Advances in Therapy, 2007

Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer's ... more Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer's disease (AD). The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Fifteen patients who fulfilled the clinical criteria for probable AD of mild to moderate severity, as put forth by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association, and as specified by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were included in the study. A control group of 15 healthy individuals from the same age and education range was included in the study.

Neurosciences, Apr 1, 2008

T he so-called "stroke," meaning the sudden occlusion of one or more brain vessels resulting in a... more T he so-called "stroke," meaning the sudden occlusion of one or more brain vessels resulting in an insufficient perfusion of the associated brain area, presents, together with cardiovascular diseases, and cancer. 1 Treatment of stroke is still limited to the optimal supportive measures. Any therapeutic approach in stroke promising to ABSTRACT ‫في‬ ‫اإلحتشاء‬ ‫حجم‬ ‫على‬ ‫ميمانتني‬ ‫عقار‬ ‫آثار‬ ‫تقييم‬ ‫األهداف:‬ ‫مؤقت‬ ‫إغالق‬ ‫عملية‬ ‫إجراء‬ ‫بعد‬ ‫العصبية‬ ‫والنتائج‬ ‫املخ‬ ‫تروية‬ ‫نقص‬ ‫الدماغي‬ )MCAO( ‫اجلرذان‬ ‫لدى‬ ‫التغطية‬ ‫وإعادة‬ ‫للشريان‬ ‫الوسطي.‬ ‫في‬ ‫داولي‬ ‫سبراكيو-‬ ‫نوع‬ ‫من‬ ً ‫بالغا‬ ً ‫جرذا‬ 30 ‫استخدام‬ ‫الطريقة:‬ ‫طريقة‬ ‫بواسطة‬ ‫الدماغ‬ ‫في‬ ‫التروية‬ ‫نقص‬ ‫إجراء‬ ‫مت‬ ‫الدراسة.‬ ‫هذه‬ ‫إعادة‬ ‫متت‬ .4-0 ‫النايلون‬ ‫غرز‬ ‫باستخدام‬ ‫اللمعة‬ ‫داخل‬ ‫اللهيب‬ ‫الدماغي‬ ‫للشريان‬ ‫اإلغالق‬ ‫عملية‬ ‫إجراء‬ ‫من‬ ‫ساعتني‬ ‫بعد‬ ‫التغطية‬ ‫مجموعتني‬ ‫الى‬ ‫عشوائي‬ ‫بشكل‬ ‫اجلرذان‬ ‫تقسيم‬ ‫مت‬ ‫الوسطي.‬ ‫ميمانتني).‬ ‫عقار‬ ‫تلقت‬ ‫التي‬ ‫و(املجموعة‬ ‫التحكم)‬ ‫(مجموعة‬ ‫وعقار‬ )0.5ml/kg( 0.9% ‫امللحي‬ ‫احمللول‬ ‫املجموعة‬ ‫تلقت‬ ‫احلصول‬ ‫مت‬ ‫املعدي.‬ ‫األنبوب‬ ‫طريق‬ ‫عن‬ )30mg/kg( ‫ميمانتني‬ ‫وجذع‬ ‫واملخيخ‬ ‫املخ‬ ‫من‬ ‫مليمترين‬ ‫بسماكة‬ ‫تاجية‬ ‫شرائح‬ ‫ثالث‬ ‫على‬ ‫تريفينيلتيترازوليوم.‬ ‫كلوريد‬ ‫من‬ 2% ‫مبحلول‬ ‫صبغها‬ ‫ومت‬ ‫الدماغ‬ ‫الدماغ‬ ‫مناطق‬ ‫قياس‬ ‫ومت‬ ‫جزء‬ ‫كل‬ ‫على‬ ‫الشفافة‬ ‫الصفحات‬ ‫وضع‬ ‫مت‬ ‫واالحتشاءات.‬ ‫(املجموع‬ ‫مجموعة‬ ‫كل‬ ‫من‬ ‫شريحة‬ 45 ‫على‬ ‫احلصول‬ ‫مت‬ ‫النتائج:‬ ‫وجذع‬ ‫واملخيخ‬ ‫املخ‬ ‫في‬ ‫بالدم‬ ‫التروية‬ ‫نقص‬ ‫منطقة‬ ‫نسبة‬ .)90 ‫التحكم‬ ‫مجموعة‬ ‫من‬ ‫أعلى‬ ‫ميمانتني‬ ‫مجموعة‬ ‫في‬ ‫الدماغ‬ ‫التحسن‬ ‫نقاط‬ ‫حددنا‬ ‫فقد‬ ‫ذلك‬ ‫إلى‬ ‫باإلضافة‬ )p>0.0001( ‫عقار‬ ‫تلقت‬ ‫التي‬ ‫اجلرذان‬ ‫في‬ ‫ساعة‬ ‫و27‬ 24 ‫عند‬ ‫العصبية‬ ‫وذو‬ ‫أفضل‬ ‫شفاء‬ ‫ميمانتني‬ ‫عقار‬ ‫مجموعة‬ ‫على‬ ‫ظهر‬ ‫ميمانتني.‬ ‫التحكم.‬ ‫مجموعة‬ ‫من‬ ‫إحصائية‬ ‫داللة‬ )p>0.0001( ‫الدم‬ ‫تروية‬ ‫نقص‬ ‫منطقة‬ ‫من‬ ‫يخفض‬ ‫قد‬ ‫ميمانتني‬ ‫عقار‬ ‫إن‬ ‫خامتة:‬ ‫يتم‬ ‫قد‬ ‫أنه‬ ‫ويبدو‬ ‫التجربة‬ ‫عليها‬ ‫أجريت‬ ‫التي‬ ‫اجلرذان‬ ‫لدى‬ ‫للدماغ‬ ‫الدماغ.‬ ‫تروية‬ ‫نقص‬ ‫في‬ ‫ميمانتني‬ ‫عقار‬ ‫من‬ ‫االستفادة‬ Objective: To evaluate the effects of memantine on infarct size in cerebral ischemia and on neurological outcome after temporary middle cerebral artery occlusion )MCAO( and reperfusion in rats.

Neurosciences (Riyadh, Saudi Arabia), 2008

To evaluate the effects of memantine on infarct size in cerebral ischemia and on neurological out... more To evaluate the effects of memantine on infarct size in cerebral ischemia and on neurological outcome after temporary middle cerebral artery occlusion (MCAO) and reperfusion in rats. In this study, performed between 2002-2004 in Dicle University School of Medicine, Diyarbakir, Turkey, 30 adult Sprague-Dawley rats were used. Cerebral ischemia was constituted by the intraluminal filament method with a 4-0 nylon suture. Reperfusion was started after 2 hours of MCAO. The rats were randomly divided into 2 groups as control and memantine. Saline 0.9% (0.5 ml/kg) and memantine (30 mg/kg) were administered via nasogastric intubations. Three coronal slices of 2 mm thickness were obtained from cerebrum, cerebellum, and brain stem, and were stained with a 2% solution of triphenyltetrazolium chloride. Transparent sheets were placed over each section and the areas of the brain and infarct were measured. Forty-five slices from each group (total 90) were obtained. Percent of ischemic area (%) in c...

Advances in Therapy, 2007

Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer&am... more Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer's disease (AD). The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Fifteen patients who fulfilled the clinical criteria for probable AD of mild to moderate severity, as put forth by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association, and as specified by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were included in the study. A control group of 15 healthy individuals from the same age and education range was included in the study. Before treatment was begun, Mini Mental State Examination (MMSE) tests were performed on all patients to evaluate cognitive function. All patients underwent baseline SPECT for evaluation of 25 different brain regions. Rivastigmine 3 mg/d was given for the first 4 wk of treatment; the dosage was then increased to 6 mg/d. The MMSE and SPECT were repeated 6 mo after the start of treatment. SPECT findings revealed that rivastigmine did not significantly affect brain perfusion in AD cases except in the inferior frontal lobe, despite stabilization and improvement noted in MMSE scores during treatment. Rivastigmine treatment of patients with AD did not significantly change brain perfusion as seen on SPECT, except in the inferior frontal lobe, but cognitive performance was stabilized or improved during the treatment course. These findings suggest the need for additional, larger studies to investigate the effects of acetylcholinesterase inhibitors on regional cerebral blood flow.

Advances in Therapy, 2007

Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer’s ... more Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer’s disease (AD). The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Fifteen patients who fulfilled the clinical criteria for probable AD of mild to moderate severity, as put forth by the National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association, and as specified by theDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were included in the study. A control group of 15 healthy individuals from the same age and education range was included in the study. Before treatment was begun, Mini Mental State Examination (MMSE) tests were performed on all patients to evaluate cognitive function. All patients underwent baseline SPECT for evaluation of 25 different brain regions. Rivastigmine 3 mg/d was given for the first 4 wk of treatment; the dosage was then increased to 6 mg/d. The MMSE and SPECT were repeated 6 mo after the start of treatment. SPECT findings revealed that rivastigmine did not significantly affect brain perfusion in AD cases except in the inferior frontal lobe, despite stabilization and improvement noted in MMSE scores during treatment. Rivastigmine treatment of patients with AD did not significantly change brain perfusion as seen on SPECT, except in the inferior frontal lobe, but cognitive performance was stabilized or improved during the treatment course. These findings suggest the need for additional, larger studies to investigate the effects of acetylcholinesterase inhibitors on regional cerebral blood flow.

Advances in Therapy, 2007

Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer’s ... more Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer’s disease (AD). The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Fifteen patients who fulfilled the clinical criteria for probable AD of mild to moderate severity, as put forth by the National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association, and as specified by theDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were included in the study. A control group of 15 healthy individuals from the same age and education range was included in the study. Before treatment was begun, Mini Mental State Examination (MMSE) tests were performed on all patients to evaluate cognitive function. All patients underwent baseline SPECT for evaluation of 25 different brain regions. Rivastigmine 3 mg/d was given for the first 4 wk of treatment; the dosage was then increased to 6 mg/d. The MMSE and SPECT were repeated 6 mo after the start of treatment. SPECT findings revealed that rivastigmine did not significantly affect brain perfusion in AD cases except in the inferior frontal lobe, despite stabilization and improvement noted in MMSE scores during treatment. Rivastigmine treatment of patients with AD did not significantly change brain perfusion as seen on SPECT, except in the inferior frontal lobe, but cognitive performance was stabilized or improved during the treatment course. These findings suggest the need for additional, larger studies to investigate the effects of acetylcholinesterase inhibitors on regional cerebral blood flow.